1  or the combination of anastrozole 1 mg with pictilisib 260 mg once per day (n = 49).

2 chical randomisation algorithm to daily oral pictilisib (340 mg in part 1 and 260 mg in part 2) or pl

3 14, we randomly allocated 61 patients to the pictilisib (41 [67%]) or placebo (20 [33%]) group.

4 atients were analysed according to presence (pictilisib 6.5 months [95% CI 3.7-9.8] vs placebo 5.1 mo

5 median progression-free survival between the pictilisib (6.6 months [95% CI 3.9-9.8]) and placebo (5.

6 3, we randomly allocated 168 patients to the pictilisib (89 [53%]) or placebo (79 [47%]) group.

7 mutations were not predictive of response to pictilisib, but there was significant interaction betwee

8 athways by the small-molecule PI3K inhibitor pictilisib (GDC-0941) and the MEK inhibitor cobimetinib

9 y assessed whether adding the PI3K inhibitor pictilisib (GDC-0941) can increase the antitumor effects

10 s occurred in 54 (61%) of 89 patients in the pictilisib group and 22 (28%) of 79 in the placebo group

11 s occurred in 15 (36%) of 42 patients in the pictilisib group and seven (37%) of 19 patients in the p

12  significant Ki-67 response was observed for pictilisib in luminal A tumors (1.01; P = .98).

13                  No further investigation of pictilisib in this setting is ongoing.

14                                              Pictilisib is an oral inhibitor of multiple PI3K isoform

15 bitors with greater selectivity than that of pictilisib might be needed to improve tolerability and p

16                                       Adding pictilisib to anastrozole significantly increases suppre

17 of this study is to establish if addition of pictilisib to fulvestrant can improve progression-free s

18                         Although addition of pictilisib to fulvestrant did not significantly improve

19         19 serious adverse events related to pictilisib treatment were reported in 14 (16%) of 89 pat

20       Four serious adverse events related to pictilisib treatment were reported in two (5%) of 42 pat

21 improve progression-free survival, dosing of pictilisib was limited by toxicity, potentially limiting